Streptavidin-ZAP [IT-27]
a tool to “piggyback” onto YOUR biotinylated material via streptavidin; targeting cells that recognize YOUR biotinylated material, eliminated via saporin
Streptavidin-ZAP [IT-27] Read More »
Blank-Streptavidin-SAP [IT-27B]
a tool for use as control with streptavidin-saporin conjugates; non-targeted via non-specific biotin-tagged peptide conjugated to streptavidin-saporin
Blank-Streptavidin-SAP [IT-27B] Read More »
Streptavidin-ZAP evaluates antibodies for targeted tumor treatment
Characterization of the First Fully Human Anti-Tem1 Scfv in Models of Solid Tumor Imaging and Immunotoxin-Based Therapy. Yuan, X, Yang, M, Chen, X, et al. (2018). Cancer Immunol Immunother 2018/01/10. Streptavidin-ZAP (Cat. #IT-27) Objective: ScFv78 was conjugated with the ribosome-inactivating protein saporin (Streptavidin-ZAP) to evaluate whether scFv78 may be used as a vehicle for theTEM1-targeted
Streptavidin-ZAP evaluates antibodies for targeted tumor treatment Read More »
Targeting Tools: Top Twenty
Top Five Targeted Toxins #1. 192-IgG-SAP (192-Saporin) (Cat. #IT-01) targets cells expressing rat p75NTR #2. Anti-DBH-SAP (Cat. #IT-03) targets cells expressing rat dopamine beta-hydroxylase (DBH) #3. mu p75-SAP (Cat. #IT-16) targets cells expressing mouse p75NTR #4. IB4-SAP (Cat. #IT-10) targets cells expressing α-D-galactopyranoside residues #5. Mac-1-SAP mouse/human (Cat. #IT-06) targets cells expressing mouse / human
Targeting Tools: Top Twenty Read More »
Screening antibodies for cancer therapeutics
Conservation of Oncofetal Antigens on Human Embryonic Stem Cells Enables Discovery of Monoclonal Antibodies against Cancer. Tan HL, Yong C, Tan BZ, Fong WJ, Padmanabhan J, Chin A, Ding V, Lau A, Zheng L, Bi X, Yang Y, & Choo A. (2018). Scientific Reports, 8 (1):11608. This study used both Hum-ZAP (Cat. #IT-22) and Streptavidin-ZAP (Cat. #IT-27)
Screening antibodies for cancer therapeutics Read More »
Streptavidin-Saporin key ingredient in Immunotoxin Cocktail
Streptavidin-ZAP[Streptavidin conjugated to Saporin](Cat. #IT-27) Objective: To determine if an immunotoxin cocktail targeted to multiple epitopes has synergistic effects on low expression level cells, which would expand the applicable range of immunotoxin therapy for cancer. Summary: The combination of immunotoxins with different mechanisms of action in an antibody cocktail will increase cytotoxic activities and decrease
Streptavidin-Saporin key ingredient in Immunotoxin Cocktail Read More »
Quantum dot-based screening identifies F3 peptide and reveals cell surface nucleolin as a therapeutic target for rhabdomyosarcoma
Dzhumashev D, Timpanaro A, Ali S, De Micheli AJ, Mamchaoui K, Cascone I, Rössler J, Bernasconi M (2022) Quantum dot-based screening identifies F3 peptide and reveals cell surface nucleolin as a therapeutic target for rhabdomyosarcoma. Cancers (Basel) 14(20):5048. doi: 10.3390/cancers14205048 Objective: To investigate targeted treatment options to improve overall survival rates and to limit long-term
Streptavidin-drug conjugates streamline optimization of antibody-based hematopoietic stem cell transplant conditioning
Yelamali AR, Chendamarai E, Ritchey JK, Rettig MP, DiPersio JF, Persaud SP (2025) Streptavidin-drug conjugates streamline optimization of antibody-based hematopoietic stem cell transplant conditioning. Blood ICT 1(3):100012. doi: 10.1016/j.bict.2025.100012 PMID: 41574174 Objective: To develop and validate a modular streptavidin based antibody drug conjugate platform for optimizing antibody mediated hematopoietic stem cell transplant conditioning. Summary: The
Advances in HIV gene therapy
Kitawi R, Ledger S, Kelleher AD, Ahlenstiel CL (2024) Advances in HIV gene therapy. Int J Mol Sci 25(5):2771. doi: 10.3390/ijms25052771 PMID: 38474018 Objective: This review highlights the various stages of ex vivo gene therapy, current research developments that have increased the efficiency and safety of this process, and a comprehensive summary of Human Immunodeficiency
Advances in HIV gene therapy Read More »
Targeted depletion of dysfunctional hematopoietic stem cells mitigates myeloid-biased differentiation in aged mice
Ren X, Wang Y, Zhang Y (2025) Targeted depletion of dysfunctional hematopoietic stem cells mitigates myeloid-biased differentiation in aged mice. Cell Discov 11:56. doi: 10.1038/s41421-025-00810-3 PMID: 40490480 Objective: To develop and evaluate a targeted strategy for depleting dysfunctional, myeloid-biased CD150-high hematopoietic stem cells (HSCs) in aged mice to restore balanced hematopoiesis and mitigate aging-related blood